Skip to main content
. 2014 Aug 5;9(8):e104235. doi: 10.1371/journal.pone.0104235

Figure 5. Correlation between CD8+ T-cell capacity to suppress HIV replication ex vivo (VIA) and percentage of baseline HIV-specific CD8+ T-cell subsets: CD8+ T-cell antiviral capacity measured at baseline versus percentage of HIV-specific CD8+ effector memory (TEM) cells (A), CD8+ terminal effector (TTE) cells (B), or CD8+ TEM/(TEM+TTE) ratio (C).

Figure 5

Antiviral CD8+ T-cell capacity measured at 12-months post-infection versus percentage of baseline HIV-specific CD8+ TEM cells (D), CD8+ TTE cells (E), or CD8+ TEM/(TEM+TTE) ratio (F). N =  11 subjects (18 specific responses). In all panels, open and filled green dots denote PHI>350 and PHI<350 subjects, respectively. All r and P values correspond to Spearman's test. VIA: Viral inhibitory activity.